Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022

Rhea-AI Summary

Unicycive Therapeutics will celebrate National Kidney Month by ringing the Nasdaq Closing Bell on March 29, 2022, at 4:00 PM ET. The event, featuring CEO Shalabh Gupta, highlights the unmet medical needs for kidney disease treatments. Unicycive is progressing towards regulatory approval for its lead drug, Renazorb, aimed at treating hyperphosphatemia, and plans to file for UNI-494 targeting acute kidney injury later in the year. The Nasdaq listing has enhanced liquidity and visibility among institutional investors.

Positive

• Ringing of the Nasdaq Closing Bell boosts company visibility and awareness of kidney diseases.
• Progress towards regulatory approval for Renazorb as a treatment for hyperphosphatemia.
• Plans to file Investigational New Drug application for UNI-494 for acute kidney injury in 2022.
• Nasdaq listing enhances liquidity and attracts institutional investors.

Negative

• None.

In Recognition of National Kidney Month

LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Unicycive team, together with the Company’s Chief Executive Officer, Shalabh Gupta, M.D., will recognize National Kidney Month and celebrate Unicycive’s July 2021 listing on the Nasdaq Stock Market by ringing the Closing Bell at Nasdaq MarketSite in Times Square, New York City. The bell ringing will take place, March 29, 2022, at 4:00 p.m. ET.

The ceremony will begin at approximately 3:45 PM Eastern time and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

“We are delighted to ring the Nasdaq closing bell in honor of National Kidney Month in order to enhance awareness of the great unmet medical need for novel therapeutics to treat patients suffering with a variety of chronic and acute kidney diseases,” stated Dr. Gupta. “Unicycive is making continued progress advancing our clinical program for Renazorb toward regulatory approval as a new treatment for hyperphosphatemia and continue to expect to file an Investigational New Drug application for UNI-494 for the treatment of acute kidney injury in the second half of 2022.”

“Listing on the Nasdaq Stock Market was a milestone achievement for Unicycive. The listing expands our audience of worldwide institutional investors, enhancing the liquidity in the trading volume of our stock and allowing Unicycive to continue to create long-term shareholder value,” added Dr. Gupta.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Investor Contact:

ir@unicycive.com
(650) 900-5470

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200

SOURCE: Unicycive Therapeutics, Inc.

FAQ

What is Unicycive Therapeutics known for?

Unicycive Therapeutics is known for developing novel treatments for kidney diseases, including Renazorb for hyperphosphatemia and UNI-494 for acute kidney injury.

When will Unicycive ring the Nasdaq Closing Bell?

Unicycive will ring the Nasdaq Closing Bell on March 29, 2022, at 4:00 PM ET.

What are the key events for Unicycive in 2022?

Key events for Unicycive in 2022 include the Nasdaq Closing Bell ceremony and plans to file for regulatory approval for UNI-494 in the second half of the year.

What is the significance of Unicycive's listing on Nasdaq?

Unicycive's listing on Nasdaq enhances the company's liquidity and visibility, allowing access to a broader audience of institutional investors.